With Potential Vaccines for Cancer, Ebola and Zika, Inovio Could Have an Explosive 2016

Other 2016 catalysts for the company, which Duncan has rated overweight, include updates from Phase 1 trials of its Ebola and MERS vaccines, … Full Article http://j.gs/5sTq

Click here to read full article